The US biotechnology company Moderna said on Monday that its experimental coronavirus vaccine was 94.5% effective at protecting people from Covid-19, according to preliminary results.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters”, Moderna’s CEO Stephane Bancel said, and added: “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease”.
On Monday, Moderna revealed that, of 95 people in the study who developed Covid-19 with symptoms so far, 90 had received a placebo and only five had received the real vaccine.
The announcement comes a week after a similar announcement from Pfizer, which determined that its vaccine candidate is 90% effective.
The final results are expected in as soon as a few weeks.